← Leaderboards
Courtney V. Fletcher
University Of Minnesota Twin Cities
$8,186,840
Attributed
$9,380,357
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $765.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,380,357 · 11
By mechanism
R01$7,038,325 · 3
P01$2,082,994 · 2
M01$259,038 · 6
Top collaborators
- Shilpa J Buch4 shared
- Nazira El-Hage4 shared
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Alvin James Beitz$4,558,430
- Virginia S Seybold$8,998,531
- Melanie A Simpson$3,771,456
- Ping-Yee Law$10,530,069
- Alice A Larson$2,766,639
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsAnti-Retroviral AgentsPharmaceutical PreparationsAntiretroviral TherapyTissuesViralBaseDoseDrug KineticsRegimenPlasmaCellsPenetrationLymph NodesProtease InhibitorResponseViral Load ResultReportingIndinavirHuman SubjectAids TherapyPersonsAntiaids AgentDesign
Grant awards (32)
Title: Pharmacokinetic, pharmacodynamic , and toxicological interactions among Opioids and Cabotegravir$694,456
R01 · FY2025 · DA
Title: Pharmacokinetic, pharmacodynamic , and toxicological interactions among Opioids and Cabotegravir$356,454
R01 · FY2024 · DA
Title: Pharmacokinetic, pharmacodynamic , and toxicological interactions among Opioids and Cabotegravir$365,335
R01 · FY2023 · DA
Title: Pharmacokinetic, pharmacodynamic , and toxicological interactions among Opioids and Cabotegravir$374,030
R01 · FY2022 · DA
The Lymphoid Tissue Pharmacology of Antiretroviral Drugs$731,313
R01 · FY2020 · AI · contact PI
The Lymphoid Tissue Pharmacology of Antiretroviral Drugs$737,007
R01 · FY2019 · AI · contact PI
The Lymphoid Tissue Pharmacology of Antiretroviral Drugs$742,442
R01 · FY2018 · AI · contact PI
The Lymphoid Tissue Pharmacology of Antiretroviral Drugs$753,498
R01 · FY2017 · AI · contact PI
The Lymphoid Tissue Pharmacology of Antiretroviral Drugs$765,790
R01 · FY2016 · AI · contact PI
Drug Penetration into Cryptic Reservoirs$367,307
P01 · FY2012 · AI · contact PI
Pharmacokinetics and Drug-Drug Interactions$212,123
P01 · FY2012 · DA · contact PI
Drug Penetration into Cryptic Reservoirs$347,867
P01 · FY2011 · AI · contact PI
Pharmacokinetics and Drug-Drug Interactions$199,423
P01 · FY2011 · DA · contact PI
Drug Penetration into Cryptic Reservoirs$220,375
P01 · FY2010 · AI · contact PI
Pharmacokinetics and Drug-Drug Interactions$148,973
P01 · FY2010 · DA · contact PI
Drug Penetration into Cryptic Reservoirs$219,325
P01 · FY2009 · AI · contact PI
Drug Penetration into Cryptic Reservoirs$367,601
P01 · FY2008 · AI · contact PI
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY IN PERSONS W/PERSISTENT VIREMIA$1,951
M01 · FY2008 · RR · contact PI
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY IN PERSONS W/PERSISTENT VIREMIA$9,888
M01 · FY2007 · RR · contact PI
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY IN PERSONS W/PERSISTENT VIREMIA$96,885
M01 · FY2006 · RR · contact PI
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY$308,000
R01 · FY2005 · AI
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY IN PERSONS W/PERSISTENT VIREMIA$96,765
M01 · FY2005 · RR
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY$307,000
R01 · FY2004 · AI
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY$8,725
M01 · FY2004 · RR
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY$304,000
R01 · FY2003 · AI
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY$302,000
R01 · FY2002 · AI
CONCENTRATION-CONTROLLED COMBINATION ANTIRETROVIRAL THERAPY$0
M01 · FY2002 · RR
CONCENTRATION-CONTROLLED COMBINATION ANTIRETROVIRAL THERAPY$0
M01 · FY2002 · RR
CONCENTRATION-CONTROLLED ANTIRETROVIRAL THERAPY$297,000
R01 · FY2001 · AI
CONCENTRATION-CONTROLLED COMBINATION ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
PHARMACOKINETIC VARIABILITY OF ANTIRETROVIRAL AGENTS IN HIV/AIDS$44,824
M01 · FY2000 · RR
CONCENTRATION-CONTROLLED COMBINATION ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR